Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Perspective Therapeutics, Inc. (CATX)
Price—Loading quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 · Dec 31 | 2022 · Jun 30 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $884,000 | $1.5M | $1.4M | $0 | $10.8M | $10.1M | $9.7M | $7.3M | $5.9M | $4.8M | $4.8M | $4.6M | $4.2M | $4.5M | $5.1M | $5.2M |
| Gross profit | — | — | $1.4M | $0 | $0 | $5.1M | $5.1M | $3.0M | $1.8M | $838,000 | $129,000 | $167,000 | −$196,471 | $150,176 | $703,204 | $1.2M |
| Gross margin | — | — | 100.00% | — | 0.00% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.70% | 3.63% | −4.66% | 3.32% | 13.87% | 22.09% |
| Research & development | $84.2M | $41.6M | $21.3M | $881,000 | $850,000 | $1.4M | $1.1M | $1.5M | $1.7M | $965,000 | $528,000 | $615,000 | $668,803 | $627,107 | $780,579 | $981,186 |
| Operating expenses | $114.4M | $92.3M | $42.4M | $8.7M | $6.4M | $8.6M | $8.6M | $8.3M | $8.6M | $7.1M | $5.2M | $4.5M | $4.4M | $4.2M | $4.3M | $4.1M |
| Operating income | −$113.6M | −$90.9M | −$40.9M | −$8.7M | −$6.4M | −$3.4M | −$3.5M | −$5.3M | −$6.7M | −$6.3M | −$5.1M | −$4.3M | −$4.6M | −$4.1M | −$3.6M | −$3.0M |
| Operating margin | −12,846.61% | −6,250.76% | −2,855.02% | — | −59.46% | −34.28% | −35.91% | −71.83% | −113.61% | −132.47% | −106.56% | −94.16% | −108.75% | −89.88% | −70.95% | −56.56% |
| EBITDA | −$110.3M | −$88.6M | −$40.0M | −$8.4M | −$6.2M | −$3.3M | −$3.3M | −$5.1M | −$6.6M | −$6.2M | −$4.6M | −$3.8M | −$3.9M | −$3.3M | −$2.8M | −$2.1M |
| EBITDA margin | −12,478.85% | −6,092.16% | −2,786.26% | — | −57.10% | −32.43% | −34.00% | −69.29% | −111.41% | −131.04% | −96.69% | −81.65% | −92.50% | −73.55% | −54.25% | −39.60% |
| Net income | −$103.1M | −$79.3M | −$46.5M | −$10.8M | −$7.3M | −$3.4M | −$3.4M | −$5.1M | −$6.7M | −$6.2M | −$4.7M | −$3.7M | −$6.0M | −$3.9M | −$3.5M | −$2.8M |
| Net profit margin | −11,665.27% | −5,452.48% | −3,243.24% | — | −67.36% | −33.69% | −35.60% | −70.33% | −113.12% | −129.43% | −98.78% | −79.92% | −141.24% | −85.22% | −68.80% | −54.25% |
| Basic EPSper basic share | -$1.40 | -$1.23 | -$1.74 | -$0.80 | -$0.50 | -$0.30 | -$0.50 | -$0.80 | -$1.20 | -$1.10 | -$0.90 | -$0.70 | -$1.60 | -$1.10 | -$12.00 | -$11.00 |
| Diluted EPSper diluted share | -$1.40 | -$1.23 | -$1.74 | — | -$0.50 | -$0.30 | -$0.50 | -$0.80 | -$1.20 | -$1.10 | -$0.90 | -$0.70 | -$1.60 | -$1.10 | -$12.00 | -$11.00 |
Owners
Reported shareholders
8.32%of listed shares
BlackRock, Inc.9.49M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.32%9.49M shares |
TCG Crossover Management, LLC | 6.94%7.92M shares |
Commodore Capital LP | 5.55%6.34M shares |
Avidity Partners Management LP | 5.52%6.3M shares |
STATE STREET CORP | 5.30%6.05M shares |
MILLENNIUM MANAGEMENT LLC | 4.31%4.91M shares |
Nantahala Capital Management, LLC | 4.08%4.65M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.89%4.44M shares |
Affinity Asset Advisors, LLC | 3.69%4.21M shares |
CITADEL ADVISORS LLC | 3.34%3.81M shares |
Spruce Street Capital LP | 3.24%3.69M shares |
Balyasny Asset Management L.P. | 2.91%3.32M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.16%2.46M shares |
MORGAN STANLEY | 1.68%1.91M shares |
GOLDMAN SACHS GROUP INC | 1.52%1.73M shares |
Nicholson Wealth Management Group, LLC | 1.42%1.62M shares |
TWO SIGMA INVESTMENTS, LP | 1.36%1.56M shares |
ADAR1 Capital Management, LLC | 1.06%1.21M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.95%1.09M shares |
DIMENSIONAL FUND ADVISORS LP | 0.94%1.07M shares |
Percentages use 114.09M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 13, 2025Form 4 | Hunt Jonathan RobertChief Accounting Officer | BuyCommon Stock | 11.0K | $2.03 | $22.3K | 59.8K |
| Nov 12, 2025Form 4 | Williamson Robert F IIIDirector | BuyCommon Stock · indirect | 9.5K | $2.10 | $19.9K | 9.9K |
| Mar 31, 2025Form 4 | Williamson Robert F IIIDirector | BuyCommon Stock | 38.1K | $2.14 | $81.6K | 109.0K |
| Mar 31, 2025Form 4 | Woods Lori ADirector | BuyCommon Stock · indirect | 23.5K | $2.13 | $50.0K | 183.5K |
| Mar 28, 2025Form 4 | Spoor Johan M.Chief Executive Officer | BuyCommon Stock · indirect | 4.7K | $2.21 | $10.3K | 4.7K |